Lantheus Holdings, Inc. (LNTH): M&A transaction — Lantheus closes $275M acquisition of Evergreen Theragnostics; adds OCTEVY and CDMO capabilities

Lantheus Holdings, Inc.

Closed acquisition of Evergreen Theragnostics for $275M cash upfront ($250M + $25M milestone achieved pre-close).
Additional contingent milestone payments up to $727.5M remain payable under the Merger Agreement.
Acquisition adds OCTEVY, a registrational-stage PET imaging agent for neuroendocrine tumors.
Adds Evergreen's radioligand therapy manufacturing infrastructure and revenue-generating CDMO business.
CEO Brian Markison: acquisition enhances capabilities across the radiopharmaceutical value chain.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Lantheus Holdings, Inc. completed an acquisition involving Evergreen Theragnostics, Inc. for approximately $275 million in cash (closed 2025-04-01).

Action: acquisition
Counterparty: Evergreen Theragnostics, Inc.
Consideration: approximately $275 million in cash
Closing: 2025-04-01

Exact text from the filing

(CDMO) services as well as drug discovery and commercialization of proprietary products. In connection with the closing of the Merger, Lantheus Medical paid approximately $275 million in cash, subject to customary adjustments as set forth in the Merger Agreement, representing the $250 million upfront cash payment and a $25 million milestone payment in respect

View on SEC.gov

95 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Lantheus Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-069927

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.